Welcome to our dedicated page for Fresenius Med Cr news (Ticker: FMS), a resource for investors and traders seeking the latest updates and insights on Fresenius Med Cr stock.
Fresenius Medical Care AG reports developments in kidney care, dialysis services, and dialysis products for individuals with renal disease. Company news commonly covers Care Delivery clinic operations, Care Enablement products such as dialysis machines, dialyzers, and the 5008X CAREsystem, and Value-Based Care activity, along with organic revenue, operating income, margins, leverage, and share buyback updates.
Other recurring items include portfolio optimization, research in hemodiafiltration, artificial intelligence and digital tools for nephrology, and governance changes affecting the Management Board and Supervisory Board. Updates also describe the company's Frankfurt and New York listings and shareholder matters tied to its ordinary shares and ADRs.
Fresenius Medical Care (NYSE:FMS) will showcase new renal research and digital innovation at the ERA Congress 2026 in Glasgow and virtually, June 3‑6.
Highlights include evidence-based hemodiafiltration studies, AI-driven tools for dialysis care, patient-centered outcomes research, and a preview of the kinexus home dialysis digital platform.
Fresenius Medical Care (NYSE:FMS) plans a new share buyback program with a total volume of around EUR 1 billion, to be executed in tranches over 12 months from launch.
The program, authorized by the May 21, 2026 AGM, is expected to start soon and follows completion of a prior EUR 1 billion buyback on April 30, 2026. According to the company, the initiative is part of its capital allocation framework, complements dividends, and is supported by strong operating cash-flow generation.
Fresenius Medical Care (NYSE:FMS) reported a milestone year with higher profitability and strong shareholder returns. Organic revenue grew 8% at constant currency and the adjusted group operating margin reached 11.3%, up from 7.9% three years earlier.
Net leverage fell to 2.5x from 3.4x in 2022. Shareholders approved a higher dividend of EUR 1.49 per share and the company completed a EUR 1 billion buyback, repurchasing 24.8 million shares (8.5% of share capital) in under one year.
The AGM also granted a new five‑year authorization for further share repurchases and highlighted FDA approval and the 2026 U.S. launch of the 5008X CAREsystem, supporting the FME Reignite strategy through 2030.
Fresenius Medical Care (NYSE:FMS) has reappointed Chief Financial Officer Martin Fischer as Management Board member for another five-year term, running until 2031.
The company highlights his role in governance, transparency, financial discipline, and support for its strategic transformation and long-term value creation.
Fresenius Medical Care (NYSE:FMS) reported Q1 2026 results with organic revenue growth of 4% and operating income excl. special items up 2% to €467m (margin 10.1%). Reported operating income fell 14% to €286m and net income declined 22% to €118m, driven by FME25+ one-time costs of €166m. The company confirmed its 2026 outlook and highlighted the rapid U.S. rollout of the 5008X CAREsystem (~100 clinics, >100,000 treatments). Share buybacks of €941m repurchased 23.3m shares by March 31, 2026.
Fresenius Medical Care (NYSE:FMS) reported strong 2025 results: Group operating income rose to €1,827m (+31% yoy), reported net income to €978m (+82% yoy) and basic EPS to €3.36 (+83% yoy). Operating income margin reached 11.3%, inside the 2025 mid-term target band.
The company recorded €238m of 2025 FME25+ savings (accumulated €804m), announced a €1.0bn buyback (first tranche completed: 14.1m shares for €586m) and proposed a €1.49 dividend (+3%).
Fresenius Medical Care (IFJPY) reported growth in U.S. home hemodialysis (HHD) adoption and launched the NxStage VersiHD with GuideMe Software. More than 14,000 U.S. patients now use NxStage systems, and new U.S. HHD starts grew 18% Jan–Apr 2024, with 927 new patients in April. VersiHD with GuideMe aims to simplify setup, shorten training and improve user experience via pictorial guidance. The device is being fully launched in the U.S. with planned global rollouts over coming years.
Fresenius Medical Care (NYSE:FMS) will accelerate the second tranche of its EUR 1 billion share buyback program and intends to repurchase around EUR 415 million of its own shares from January 12 to May 8, 2026. The first tranche was completed ahead of schedule on December 29, 2025, and the company expects the full program to be completed in less than a year under its FME Reignite capital allocation framework. Management attributes the acceleration to strong cash-flow generation and continued business momentum. Regular progress updates will be provided on the company's investor website.
Fresenius Medical Care (NYSE:FMS) appointed Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board, effective Jan 1, 2026. He succeeds Franklin W. Maddux, who will retire at year-end as part of a planned transition.
Hugh-Jones joins from Volastra Therapeutics after leadership roles at Allergan, Pfizer and Sanofi. The company highlighted the 5008X CAREsystem rollout in the U.S. and noted its network serves ~294,000 patients across 3,628 clinics worldwide.
Fresenius Medical Care (FMS) reported Q3 2025 results showing accelerated profitability and strong organic revenue growth. Group revenue was EUR 4,885m (+3% reported, +8% cc, +10% organic). Operating income excluding special items rose 22% (+28% cc) to EUR 574m, lifting the margin to 11.7%. Reported net income was EUR 275m (+29%) and basic EPS was EUR 0.94 (+30%).
Key actions: initial EUR 1.0bn buyback announced (first tranche up to EUR 600m; EUR 151m repurchased as of Sept 30), ownership increase in Interwell Health (EUR 312m), and FME25+ cost savings of EUR 47m in Q3 (YTD EUR 174m).